Imifoplatin is a Small Molecule owned by Promontory Therapeutics, and is involved in 11 clinical trials, of which 4 were completed, 5 are ongoing, and 2 are planned.
PT-112 act as pro-apoptotic agent without targeting DNA. It stimulates apoptosis, a normal process which is often impaired or dysfunctional in tumor cells. Phosphaplatin compounds activate specific genes, promote expression of trans-membrane proteins of cancer cells and transmit a set of signals to the interior of the cells thereby killing them and preventing spread of the disease without damaging DNA in the cell nuclei.
The revenue for Imifoplatin is expected to reach a total of $143m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Imifoplatin NPV Report.
Imifoplatin was originated by Ohio University and is currently owned by Promontory Therapeutics. SciClone Pharmaceuticals Holdings is the other company associated in development or marketing of Imifoplatin.
PT-112 is under development for the treatment of advanced solid tumors including squamous or non-squamous non small cell lung cancer (NSCLC), basal cell carcinoma, pancreatic cancer, ovarian cancer, gallbladder cancer, gastric cancer, cholangiocarcinoma, colorectal cancer, thymoma, thymic carcinoma, neuroendocrine carcinoma, intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), metastatic hepatocellular carcinoma, urothelial carcinoma (UC), squamous cell carcinoma of the head and neck (SCCHN), castration-resistant prostate cancer (CRPC), breast cancer, liver cancer or hepatic metastasis and relapsed or refractory multiple myeloma. The drug candidate is administered intravenously. It is a phosphaplatin which is a combination of phosphate and platinum.
SciClone Pharmaceuticals Holdings Overview
SciClone Pharmaceuticals Holdings (SciClone) develops and commercializes products for the treatment of cancer and immunology. The company’s pipe line products include daya sin, zotye, nomic, angel, ando student, he lesheng, mesna, methotrexate injection, algos and faroda among others. Its under-development products comprise Naxitamab, Circumcising, Vibativ, Vaborem, RRx-001, PEN-866, PT-112, ABTL-0812 and HSP90-PI3K. It also markets Zadaxin (Thymalfasin), an immunostimulatory agent indicated for the treatment of hepatitis as an immune system enhancer. SciClone is headquartered in Hongkong.
The company reported revenues of (Renminbi) CNY2,518.5 million for the fiscal year ended December 2021 (FY2021), an increase of 31.3% over FY2020. In FY2021, the company’s operating margin was 42%, compared to an operating margin of 43.5% in FY2020. In FY2021, the company recorded a net margin of 36.7%, compared to a net margin of 39.3% in FY2020.
Quick View – Imifoplatin
|Highest Development Stage|